证券代码：688016 证券简称：心脉医疗 公告编号：2025-044 上海微创心脉医疗科技（集团）股份有限公司 关于召开2025年第一次临时股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东大会类型和届次 2025年第一次临时股东大会 召开日期时间：2025 年 11 月 14 日 14 点 00 分 召开地点：上海市浦东新区康新公路 3399 弄 1 号楼 1 层公司会议室 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 11 月 14 日 至2025 年 11 月 14 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 股东大会召开日期：2025年11月14日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 （二） 股东大会召集人：董事会 （三） 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 （四） ...

Revenue and Profit - The company's revenue for Q3 2025 reached ¥300,350,261.64, representing a year-over-year increase of 64.68%[4] - Total profit for the period was ¥130,607,340.82, a decrease of 20.88% compared to the same period last year[4] - Net profit attributable to shareholders was ¥114,408,672.85, down 23.63% year-over-year[4] - Total operating revenue for the first three quarters of 2025 reached ¥1,014,780,041.62, an increase from ¥969,564,236.70 in the same period of 2024, representing a growth of approximately 4.3%[19] - Operating profit for the first three quarters of 2025 was ¥497,462,954.23, compared to ¥637,790,237.07 in 2024, reflecting a decrease of approximately 22.0%[20] - Net profit for the first three quarters of 2025 was ¥423,065,173.14, down from ¥547,177,167.51 in 2024, a decline of about 22.7%[20] - Basic earnings per share for the first three quarters of 2025 were ¥3.54, compared to ¥4.49 in the same period of 2024, a decrease of approximately 21.2%[21] Expenses and Costs - Research and development expenses totaled ¥25,851,086.52, a decrease of 28.12% compared to the same period last year[5] - Total operating costs for the first three quarters of 2025 were ¥563,934,629.28, up from ¥443,293,120.87 in 2024, indicating an increase of about 27.3%[20] - The company paid CNY 43,558,034.80 in dividends and interest in the first three quarters of 2025, a decrease from CNY 248,178,759.00 in the same period of 2024, reflecting a reduction of about 82.5%[25] Assets and Liabilities - The total assets of the company increased by 10.27% year-over-year, reaching ¥4,732,362,656.89[5] - Total assets increased to ¥4,732,362,656.89 in 2025 from ¥4,291,597,451.31 in 2024, marking a growth of about 10.3%[16] - Total liabilities rose to ¥750,072,716.20 in 2025, compared to ¥469,125,424.12 in 2024, an increase of approximately 59.9%[16] - Non-current liabilities totaled ¥135,054,880.90 in 2025, slightly up from ¥130,086,642.62 in 2024, indicating a growth of about 3.7%[16] - The company's total equity increased to ¥3,982,289,940.69 in 2025 from ¥3,822,472,027.19 in 2024, reflecting a growth of approximately 4.2%[16] Cash Flow - The company reported a cash flow from operating activities of ¥363,201,648.36, a decrease of 3.26% year-over-year[4] - In the first three quarters of 2025, the net cash flow from operating activities was CNY 363,201,648.36, compared to CNY 375,446,862.07 in the same period of 2024, reflecting a decrease of approximately 2.9%[24] - Total cash inflow from investment activities in the first three quarters of 2025 was CNY 2,934,168,253.08, while cash outflow was CNY 4,305,020,875.92, resulting in a net cash flow of -CNY 1,370,852,622.84[25] - The total cash outflow for operating activities in the first three quarters of 2025 was CNY 598,595,046.84, compared to CNY 651,367,599.52 in 2024, indicating a decrease of about 8.1%[24] - The company's cash inflow from financing activities was CNY 126,000,000.00 in the first three quarters of 2025, compared to CNY 35,000,000.00 in the same period of 2024, marking an increase of approximately 260%[25] Shareholder Information - Total number of common shareholders at the end of the reporting period is 15,990[11] - MicroPort Endovascular holds 39.77% of shares, totaling 49,025,370 shares[11] - The company has repurchased a total of 1,263,043 shares, accounting for 1.02% of total share capital, with a total expenditure of RMB 132,745,761.84[13] - The second phase of the share repurchase plan has been completed as of the report date[13] - The company has not disclosed any significant changes in shareholder relationships or actions among the top shareholders[12] Operational Insights - The company aims to optimize its R&D team structure and improve the output ratio of R&D investments, leading to a reduction in R&D spending[9] - The company continues to expand its overseas market presence, enhancing product competitiveness and steadily increasing production and sales volumes[9] - The company has not identified any other significant operational issues during the reporting period[13] - The cash flow from operating activities showed a slight increase in 2025 compared to 2024, indicating stable operational performance despite challenges in sales revenue[24] - The company is not applying new accounting standards or interpretations for the first time in 2025, maintaining consistency in financial reporting[26]

以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 《心脉医疗：关于第二期股份回购实施结果暨股份变动的公告》 公司近日发布公告称，关于第二期股份回购实施结果暨股份变动情况如下：证券代码：688016，证券简 称：心脉医疗。公司于2024年10月28日至2025年10月27日期间实施第二期股份回购，回购价格上限为 176.73元/股，预计回购金额10,000万元至20,000万元。截至2025年10月27日，公司以集中竞价交易方式 累计回购股份1,333,943股，占公司总股本的1.08%，回购价格区间为84.26元/股至120元/股，支付资金总 额140,098,144.06元（不含交易费用）。本次回购符合董事会审议通过的方案，资金来源为自有资金和 股票回购专项贷款。回购股份将全部用于员工持股计划或股权激励，并在公告披露后3年内使用完毕， 未使用部分将依法注销。回购后公司股权分布仍符合上市条件。 最新公告列表 截至2025年10月29日收盘，心脉医疗（688016）报收于105.42元，较前一交易日上涨1.29%，最新总市 值为129. ...

Group 1 - The company approved a second phase of share repurchase plan, allowing for the repurchase of shares at a price not exceeding RMB 180 per share, with a total repurchase amount between RMB 100 million and RMB 200 million [2] - The maximum repurchase price was adjusted to RMB 178.35 per share after the 2024 semi-annual profit distribution, and further adjustments were made to RMB 178.01 and RMB 176.73 per share following subsequent profit distributions [3] - The company completed the share repurchase on October 27, 2025, acquiring a total of 1,333,943 shares, which represents 1.08% of the total share capital, at an average price of RMB 105.03 per share, totaling approximately RMB 140.1 million [4] Group 2 - The repurchased shares will be used for employee stock ownership plans or equity incentives, with all shares expected to be utilized within three years from the announcement date [6] - The company confirmed that there were no stock trades by directors, supervisors, and major shareholders during the repurchase period [5] - The repurchased shares will not enjoy rights such as profit distribution or voting rights until they are used, and if not utilized within the specified period, the company will proceed with capital reduction procedures [6]

公司公告汇总 心脉医疗：关于第二期股份回购实施结果暨股份变动的公告 截至2025年10月28日收盘，心脉医疗(688016)报收于104.08元，下跌0.88%，换手率0.88%，成交量1.08 万手，成交额1.13亿元。 当日关注点 交易信息汇总资金流向 10月28日主力资金净流出1327.68万元，占总成交额11.72%；游资资金净流入434.76万元，占总成交额 3.84%；散户资金净流入892.92万元，占总成交额7.88%。 证券代码：688016，证券简称：心脉医疗。公司于2024年10月28日至2025年10月27日期间实施第二期股 份回购，回购价格上限为176.73元/股，预计回购金额10,000万元至20,000万元。截至2025年10月27日， 公司以集中竞价交易方式累计回购股份1,333,943股，占公司总股本的1.08%，回购价格区间为84.26元/ 股至120元/股，支付资金总额140,098,144.06元（不含交易费用）。本次回购符合董事会审议通过的方 案，资金来源为自有资金和股票回购专项贷款。回购股份将全部用于员工持股计划或股权激励，并在公 告披露后3年内使用完毕，未使用部分将 ...

Group 1 - The company, Xinmai Medical, announced its first share buyback on December 6, 2024, through centralized bidding, completing the buyback by October 27, 2025 [1] - A total of approximately 1.33 million shares were repurchased, accounting for 1.08% of the company's total share capital, with a maximum transaction price of 120 CNY per share and a minimum of 84.26 CNY per share, resulting in an average buyback price of 105.03 CNY per share [1] - The total funds used for the buyback amounted to approximately 140 million CNY, reaching the lower limit of the buyback plan without exceeding the upper limit [1] Group 2 - For the year 2024, Xinmai Medical's revenue composition indicates that 99.7% of its revenue comes from products related to aortic and peripheral vascular applications, while other businesses contribute only 0.3% [1] - As of the report date, the market capitalization of Xinmai Medical is 12.8 billion CNY [1]

证券代码：688016 证券简称：心脉医疗 公告编号：2025-043 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日（第二期） | 2024/10/30 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限（第二期） | 年 月 2024 10 10 | 28 | 日~2025 | 年 | 月 | 27 | 日 | | 预计回购金额（第二期） | 10,000万元~20,000万元 | | | | | | | | 回购价格上限（第二期） | 176.73元/股 | | | | | | | | 回购用途（第二期） | □减少注册资本 √用于员工持股计划或股权激励 □用于转换公司可转债 | | | | | | | | | □为维护公司价值及股东权益 | | | | | | | | 实际回购股数（第二期） | 1,333,943股 | | | | | | | | 实际回购股数占总股本比例 | 1. ...

Core Viewpoint - The stock of Xinmai Medical (688016) has shown a decline in both price and trading volume, with significant net outflows from retail and speculative investors, indicating potential concerns about the company's financial performance and market sentiment [1][2]. Financial Performance - As of the latest report, Xinmai Medical's total revenue for the first half of 2025 was 714 million yuan, representing a year-on-year decrease of 9.24% [3]. - The net profit attributable to shareholders for the same period was 315 million yuan, down 22.03% year-on-year, while the non-recurring net profit was 271 million yuan, reflecting a decline of 29.96% [3]. - The company's second-quarter performance showed a revenue of 382 million yuan, a decrease of 10.92% year-on-year, and a net profit of 185 million yuan, down 15.61% [3]. Market Position - Xinmai Medical's total market capitalization is 13.127 billion yuan, which is higher than the industry average of 11.795 billion yuan, ranking 25th in the industry [3]. - The company has a net asset value of 4.058 billion yuan, also above the industry average, ranking 34th [3]. - The price-to-earnings ratio (P/E) stands at 20.86, significantly lower than the industry average of 66.45, ranking 13th [3]. Profitability Metrics - The gross margin for Xinmai Medical is 69.19%, which is substantially higher than the industry average of 51.85%, ranking 22nd [3]. - The net profit margin is 43.48%, far exceeding the industry average of 10.39%, ranking 2nd [3]. - Return on equity (ROE) is reported at 8.16%, compared to the industry average of 1.8%, ranking 12th [3]. Investment Sentiment - In the past 90 days, 11 institutions have rated the stock, with 9 buy ratings and 2 hold ratings, indicating a generally positive outlook despite recent performance [4]. - The average target price set by institutions for Xinmai Medical is 136.03 yuan, suggesting potential upside from the current trading price [4].

Core Viewpoint - The stock of Xinmai Medical (688016) has experienced a decline, with a closing price of 107.63 yuan on October 13, 2025, down 2.67% from the previous day [1] Group 1: Stock Performance and Trading Data - On October 13, 2025, the stock had a turnover rate of 1.46%, with a trading volume of 18,000 hands and a total transaction amount of 193 million yuan [1] - The net inflow of main funds was 7.05 million yuan, accounting for 3.65% of the total transaction amount, while retail investors saw a net outflow of 5.28 million yuan, representing 2.73% of the total [1][2] - Over the past five days, the stock has shown a downward trend, with a closing price of 110.58 yuan on October 10, 2025, down 1.90%, and a net inflow of main funds of 7.95 million yuan [2] Group 2: Financing and Margin Trading Data - On October 13, 2025, the financing balance was 494 million yuan, with a net repayment of 38,300 yuan [3] - The stock had a margin trading balance of 496 million yuan, with a margin balance of 2.39 million yuan [3] - The stock's margin trading data indicates a consistent level of activity, with a total margin trading balance of 496 million yuan over the past five days [3] Group 3: Company Financial Performance - Xinmai Medical reported a main revenue of 714 million yuan for the first half of 2025, a year-on-year decrease of 9.24%, and a net profit of 315 million yuan, down 22.03% [5] - The company's gross profit margin stands at 69.19%, significantly higher than the industry average of 51.85% [5] - The company ranks 15th in net profit within the medical device industry, with a net profit margin of 43.48%, placing it second in the industry [5] Group 4: Industry Comparison and Ratings - Xinmai Medical has a total market value of 13.267 billion yuan, which is above the industry average of 11.888 billion yuan [5] - The company has received 12 ratings from institutions in the past 90 days, with 10 buy ratings and 2 hold ratings, and an average target price of 136.03 yuan [6]

Core Viewpoint - The company, Xinmai Medical, announced a cash dividend distribution and adjusted its share repurchase plan following the distribution, reflecting its ongoing commitment to returning value to shareholders [1][2][3]. Trading Information Summary - As of October 10, 2025, Xinmai Medical's stock closed at 110.58 yuan, down 1.9%, with a turnover rate of 1.27% and a trading volume of 15,600 shares, amounting to a total transaction value of 174 million yuan [1]. - On the same day, the net inflow of main funds was 7.95 million yuan, accounting for 4.56% of the total transaction value, while retail investors experienced a net outflow of 4.23 million yuan, representing 2.43% of the total transaction value [1][3]. Company Announcement Summary - Xinmai Medical announced a cash dividend of 1.3 yuan per share (tax included), with the record date set for October 16, 2025, and the ex-dividend date on October 17, 2025. The total cash dividend distribution amounts to approximately 157.19 million yuan (tax included) based on the adjusted share count [1][2]. - Following the dividend distribution, the upper limit for the second phase of the share repurchase plan was adjusted from 178.01 yuan per share to 176.73 yuan per share, effective from October 17, 2025. The total repurchase amount is set between 100 million yuan and 200 million yuan [2][4]. - As of September 30, 2025, the company had repurchased a total of 1,263,043 shares, representing 1.02% of the total share capital, with a cumulative repurchase amount of approximately 133 million yuan [3][4].